menu search

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes. Recruitment is underway for the Phase 2 CELIA study further investigating clinical efficacy and safety. […] The post New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation... Read More
Posted: Oct 25 2023, 14:51
Author Name: forextv
Views: 112548

Search within

Pages Search Results: